- Poster presentation
- Open Access
Antiretroviral tolerability and efficacy after switch to saquinavir in PI-experienced patients: 48-week analysis of the German Rainbow Cohort
© Stephan et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Viral Load
- Total Cholesterol Level
- Virological Failure
- Switching Treatment
The aim of the Rainbow Cohort is to assess the tolerability and efficacy of initiating treatment with, or switching treatment to the saquinavir (SQV) 500 mg film-coated tablet formulation. We present the final 48-week subgroup analysis of PI-experienced, but SQV-naïve patients.
Multicenter, prospective, open label, observational cohort study. Tolerability assessment included changes in lipids – stratified according to baseline (BL) levels – from BL to week 48. Efficacy assessment included changes in CD4 count and viral load (VL). Changes to baseline were tested for significance with Wilcoxon signed rank test.
These data confirm that SQV/r is effective and well tolerated in PI-experienced, SQV-naïve patients in a real-life clinical setting. Most relevant improvements in triglycerides and total cholesterol levels were observed in patients with baseline grade III–IV elevation.
This article is published under license to BioMed Central Ltd.